PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Werbeagentur & PR-Agentur co-operate

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Granulox Wound Spray Granted CE Mark Thanks to Diapharm  - Granulox wound spray is a new medical device that improves oxygen supply to chronic wounds, using haemoglobin as the transporter. SastoMed has engaged Diapharm to perform the CE certification process in Germany - Diapharm.com
Granulox Wound Spray Granted CE Mark Thanks to Diapharm

 

NewswireToday - /newswire/ - Luebeck, Germany, 2012/04/24 - Granulox wound spray is a new medical device that improves oxygen supply to chronic wounds, using haemoglobin as the transporter. SastoMed has engaged Diapharm to perform the CE certification process in Germany - Diapharm.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

With its wound spray Granulox, SastoMed GmbH has recently brought a new medical device to market. It improves oxygen supply to chronic wounds, using haemoglobin as the transporter. SastoMed has engaged Diapharm (diapharm.com) to perform the certification of the Class III medical device, and the outcome has been a great success: only 16 months elapsed between Day 1 and the granting of an EU-wide CE mark. This period of time was much less than originally expected. Looking forward, Diapharm will also be performing the legal role of manufacturer of the wound spray through its ISO 13485 certified subsidiary HÄLSA Pharma GmbH. Manufacturing and batch release of the medical device will take place under the HÄLSA quality management system. Granulox is on sale now.

Granulox wound spray new on the market
“This wound spray makes it possible to apply a known principle in an uncomplicated manner for the first time – both in hospitals and in an outpatient setting,” explains Michael Sander, Director of SastoMed GmbH. As a result of easier diffusion, the haemoglobin in the product transports oxygen from the air to the wound bed and improves oxygen supply. Certification as a Class III medical device has been particularly ambitious, emphasises Sander, whose company has obtained the world-wide patent rights and rights of sale for the technology: “We are grateful to Diapharm that market release in Europe has now come about so quickly.” The technology behind Granulox comes from Sangui Bio Tech. The efficacy of the physical process has been proven in clinical trials.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Werbeagentur & PR-Agentur co-operate

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Granulox Wound Spray Granted CE Mark Thanks to Diapharm

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Christian Rieke - Co-Operate.net 
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Werbeagentur & PR-Agentur co-operate securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Werbeagentur & PR-Agentur co-operate / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  JobsWare.com





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)